A Hydrazine-Hydrazone Adamantine Compound Shows Antimycobacterial Activity and Is a Probable Inhibitor of MmpL3

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 Oct 27

PMID 36296721

Authors

Julien Briffotaux

Yanji Xu

Wei Huang

Zhen Hui

Xiao Wang

Brigitte Gicquel

Shengyuan Liu

Affiliations

Soon will be listed here.

Abstract

Tuberculosis remains an important cause of morbidity and mortality throughout the world. Notably, an important number of multi drug resistant cases is an increasing concern. This problem points to an urgent need for novel compounds with antimycobacterial properties and to improve existing therapies. Whole-cell-based screening for compounds with activity against complex strains in the presence of linezolid was performed in this study. A set of 15 bioactive compounds with antimycobacterial activity in vitro were identified with a minimal inhibitory concentration of less than 2 µg/mL. Among them, compound is a small molecule with a chemical structure consisting of an adamantane moiety and a hydrazide-hydrazone moiety. Whole genome sequencing of spontaneous mutants resistant to the compounds suggested compound to be a new inhibitor of MmpL3. This compound binds to the same pocket as other already published MmpL3 inhibitors, without disturbing the proton motive force of BCG and . Compound showed a strong activity against a panel ofclinical strains of in vitro. This compound showed no toxicity against mammalian cells and protected larvae against BCG infection. These results suggest that compound is a promising anti-TB agent with the potential to improve TB treatment in combination with standard TB therapies.

Citing Articles

Hydrazones, hydrazones-based coinage metal complexes, and their biological applications.

Tafere D, Gebrezgiabher M, Elemo F, Sani T, Atisme T, Ashebr T RSC Adv. 2025; 15(8):6191-6207.

PMID: 40034805 PMC: 11873977. DOI: 10.1039/d4ra07794f.

Alternatives to animal models to study bacterial infections.

Hu C, Yang W Folia Microbiol (Praha). 2023; 68(5):703-739.

PMID: 37632640 DOI: 10.1007/s12223-023-01084-6.

-A Model for the Study of aPDT-Prospects and Drawbacks.

Bugyna L, Kendra S, Bujdakova H Microorganisms. 2023; 11(6).

PMID: 37374956 PMC: 10301295. DOI: 10.3390/microorganisms11061455.

Recent Advances in Anti-Tuberculosis Drug Discovery Based on Hydrazide-Hydrazone and Thiadiazole Derivatives Targeting InhA.

Teneva Y, Simeonova R, Valcheva V, Angelova V Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111241 PMC: 10140854. DOI: 10.3390/ph16040484.

Galleria mellonella-intracellular bacteria pathogen infection models: the ins and outs.

Asai M, Li Y, Newton S, Robertson B, Langford P FEMS Microbiol Rev. 2023; 47(2).

PMID: 36906279 PMC: 10045907. DOI: 10.1093/femsre/fuad011.

References

Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J . Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother. 2005; 56(5):968-74. DOI: 10.1093/jac/dki319. View

Bolla J . Targeting MmpL3 for anti-tuberculosis drug development. Biochem Soc Trans. 2020; 48(4):1463-1472. PMC: 7458404. DOI: 10.1042/BST20190950. View

Viljoen A, Dubois V, Girard-Misguich F, Blaise M, Herrmann J, Kremer L . The diverse family of MmpL transporters in mycobacteria: from regulation to antimicrobial developments. Mol Microbiol. 2017; 104(6):889-904. DOI: 10.1111/mmi.13675. View

Ioerger T, OMalley T, Liao R, Guinn K, Hickey M, Mohaideen N . Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One. 2013; 8(9):e75245. PMC: 3781026. DOI: 10.1371/journal.pone.0075245. View

Rollas S, Gulerman N, Erdeniz H . Synthesis and antimicrobial activity of some new hydrazones of 4-fluorobenzoic acid hydrazide and 3-acetyl-2,5-disubstituted-1,3,4-oxadiazolines. Farmaco. 2002; 57(2):171-4. DOI: 10.1016/s0014-827x(01)01192-2. View

Li W, Obregon-Henao A, Wallach J, North E, Lee R, Gonzalez-Juarrero M . Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3. Antimicrob Agents Chemother. 2016; 60(9):5198-207. PMC: 4997843. DOI: 10.1128/AAC.00826-16. View

Zhang B, Li J, Yang X, Wu L, Zhang J, Yang Y . Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target. Cell. 2019; 176(3):636-648.e13. DOI: 10.1016/j.cell.2019.01.003. View

Asai M, Li Y, Khara J, Robertson B, Langford P, Newton S . : An Infection Model for Screening Compounds Against the Complex. Front Microbiol. 2019; 10:2630. PMC: 6882372. DOI: 10.3389/fmicb.2019.02630. View

Remuinan M, Perez-Herran E, Rullas J, Alemparte C, Martinez-Hoyos M, Dow D . Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. PLoS One. 2013; 8(4):e60933. PMC: 3629081. DOI: 10.1371/journal.pone.0060933. View

10.

Li W, Stevens C, Pandya A, Darzynkiewicz Z, Bhattarai P, Tong W . Direct Inhibition of MmpL3 by Novel Antitubercular Compounds. ACS Infect Dis. 2019; 5(6):1001-1012. PMC: 6580365. DOI: 10.1021/acsinfecdis.9b00048. View

11.

Abdelrahman M, Salama I, Gomaa M, Elaasser M, Abdel-Aziz M, Soliman D . Design, synthesis and 2D QSAR study of novel pyridine and quinolone hydrazone derivatives as potential antimicrobial and antitubercular agents. Eur J Med Chem. 2017; 138:698-714. DOI: 10.1016/j.ejmech.2017.07.004. View

12.

Su C, Klenotic P, Cui M, Lyu M, Morgan C, Yu E . Structures of the mycobacterial membrane protein MmpL3 reveal its mechanism of lipid transport. PLoS Biol. 2021; 19(8):e3001370. PMC: 8384468. DOI: 10.1371/journal.pbio.3001370. View

13.

Entwistle F, Coote P . Evaluation of greater wax moth larvae, Galleria mellonella, as a novel in vivo model for non-tuberculosis Mycobacteria infections and antibiotic treatments. J Med Microbiol. 2018; 67(4):585-597. DOI: 10.1099/jmm.0.000696. View

14.

Shetty A, Xu Z, Lakshmanan U, Hill J, Choong M, Chng S . Novel Acetamide Indirectly Targets Mycobacterial Transporter MmpL3 by Proton Motive Force Disruption. Front Microbiol. 2018; 9:2960. PMC: 6289072. DOI: 10.3389/fmicb.2018.02960. View

15.

. EUCAST Definitive Document E.Def 1.2, May 2000: Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect. 2001; 6(9):503-8. DOI: 10.1046/j.1469-0691.2000.00149.x. View

16.

Williams J, Haiderer E, Coulson G, Conner K, Ellsworth E, Chen C . Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance. Antimicrob Agents Chemother. 2019; 63(10). PMC: 6761494. DOI: 10.1128/AAC.00547-19. View

17.

La Rosa V, Poce G, Canseco J, Buroni S, Pasca M, Biava M . MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother. 2011; 56(1):324-31. PMC: 3256021. DOI: 10.1128/AAC.05270-11. View

18.

Chawla M, Parikh P, Saxena A, Munshi M, Mehta M, Mai D . Mycobacterium tuberculosis WhiB4 regulates oxidative stress response to modulate survival and dissemination in vivo. Mol Microbiol. 2012; 85(6):1148-65. PMC: 3438311. DOI: 10.1111/j.1365-2958.2012.08165.x. View

19.

Zhou Y, Gammeltoft K, Galli A, Offersgaard A, Fahnoe U, Ramirez S . Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro. Viruses. 2021; 13(10). PMC: 8537953. DOI: 10.3390/v13102082. View

20.

Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps A . Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother. 2015; 70(5):1558-66. DOI: 10.1093/jac/dku553. View